50290-51-2Relevant academic research and scientific papers
Halogen-Containing 2-methylpyrimido[1,2-a]-benzimidazol-4(10H)-ones
Ulomskiy,El'Tsov,Borisov,Savateev,Voinkov,Fedotov,Rusinov
, p. 1005 - 1013 (2014)
We have synthesized a series of 3-halo-substituted pyrimidobenzimidazolones and studied the alkylation reaction of the obtained derivatives.
Synthesis, Crystal structure, Hirshfeld surface Analysis and computational approach of new 2-methylbenzimidazo[1,2-a]pyrimidin-4(1H)-one
El Bakri, Youness,Lai, Chin-Hung,Karthikeyan, Subramani,Guo, Lei,Ahmad, Sajjad,Ben-Yahya, Ali,Mague, Joel T.,Essassi, El Mokhtar
, (2021)
The present article describes the synthesis of the new compound 2-methylbenzimidazo[1,2-a]pyrimidin-4(1H)-one. The electronic and spatial structure of this molecule was studied theoretically and experimentally. The title molecule, C11H9N3O, is slightly twisted and bowed based on the recent crystallographic study, while the DFT-B3LYP study shows that the title compound is fully planar in the gas phase. This discrepancy between the experimentally determined geometry and the B3LYP optimized one may be due to the crystal packing. In the crystal, a layer structure is formed by N—H???N and C—H???O hydrogen bonds together with π-stacking and C—H???π(ring) interactions. However, the Hirshfled surface analysis showed that the most important intermolecular interaction for the title compound is the H???H contact. Based on the wide biological interest, molecular docking and molecular dynamics studies were performed for the above titled compound with the poly(ADP-ribose)polymerase (PARP) enzyme target and the result shows that there is a good binding affinity and stability in PARP complex system.
MRGX Receptor Antagonists
-
Paragraph 0300; 0310; 0311, (2021/05/07)
The invention relates to a method for preventing or treating a disease or disorder that is associated with the MrgX2 receptor. The invention also relates to MrgX2 antagonists and physiologically acceptable salts thereof. The invention also relates to pharmaceutical compositions and dosage forms comprising an MrgX2 antagonist.
Copper-Catalyzed Domino Synthesis of Benzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-ones using Cyanamide as a Building Block
Lou, Zhenbang,Wu, Xudong,Yang, Haijun,Zhu, Changjin,Fu, Hua
supporting information, p. 3961 - 3968 (2016/01/25)
An efficient and practical copper-catalyzed domino synthesis of benzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-ones has been developed. The protocol uses N-(2-halophenyl)-3-alkylpropiolamides and cyanamide as the starting materials, inexpensive copper(I) iodide and pipecolinic acid as the catalyst and ligand, and the corresponding products were obtained in moderate to good yields.
Synthesis and characterization of some novel 2-(trifluoromethyl)pyrimido- [1,2-a]benzimidazoles and pyrimido[1,2-a]benzimidazol-2H-ones of biological interest
Zanatta, Nilo,Amaral, Simone S.,Esteves-Souza, Andressa,Echevarria, Aurea,Brondani, Patricia B.,Flores, Darlene C.,Bonacorso, Helio G.,Flores, Alex F. C.,Martins, Marcos A. P.
, p. 2305 - 2312 (2008/02/02)
The synthesis of some potentially active 2-(trifluoromethyl)pyrimido [1,2-a]benzimidazoles and pyrimido[1,2-a]benzimidazol-2(1H)-ones by the cyclization of 4-alkoxyvinyl trifluoro(chloro)methyl ketones with 2-aminobenzimidazole is described. The structure
